Literature DB >> 31121608

A Comprehensive Overview of Coagulation Factor V and Congenital Factor V Deficiency.

Shadi Tabibian1, Yavar Shiravand2, Mahmood Shams3, Majid Safa1, Mohammad Saeed Gholami1, Farshad Heydari1, Abbas Ahmadi4, Jamal Rashidpanah5, Akbar Dorgalaleh1.   

Abstract

Coagulation factor (F) V is a glycoprotein that plays an essential role in the formation of the prothrombinase complex, which is critical for progressing clot formation. FV deficiency is a rare bleeding disorder with an estimated incidence of one per 1 million in the general population. The disorder is manifested with a wide array of clinical bleeding events. The most common bleeding features of FV deficiency are mucosal bleedings. Life-threatening manifestations are rarely seen in this disorder. FV deficiency is diagnosed using routine coagulation tests and FV activity assay. A wide spectrum of mutations including missense, nonsense, and frameshift is observed throughout the F5 gene. Although fresh frozen plasma is the dominant therapeutic choice, a newly introduced plasma-derived FV concentrate was found effective in in vitro correction of prothrombin time, activated partial thromboplastin time, and thrombin generation parameters in severe FV deficiency and should provide more targeted treatment for patients with FV deficiency in the future. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31121608     DOI: 10.1055/s-0039-1687906

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  7 in total

1.  Development and Characterization of a Factor V-Deficient CRISPR Cell Model for the Correction of Mutations.

Authors:  Luis Javier Serrano; Mariano Garcia-Arranz; Juan A De Pablo-Moreno; José Carlos Segovia; Rocío Olivera-Salazar; Damián Garcia-Olmo; Antonio Liras
Journal:  Int J Mol Sci       Date:  2022-05-22       Impact factor: 6.208

2.  Standardization of Coagulation Factor V Reference Intervals, Prothrombin Time, and Activated Partial Thromboplastin Time in Mice for Use in Factor V Deficiency Pathological Models.

Authors:  Juan A De Pablo-Moreno; Antonio Liras; Luis Revuelta
Journal:  Front Vet Sci       Date:  2022-03-28

Review 3.  The Vascular Endothelium and Coagulation: Homeostasis, Disease, and Treatment, with a Focus on the Von Willebrand Factor and Factors VIII and V.

Authors:  Juan A De Pablo-Moreno; Luis Javier Serrano; Luis Revuelta; María José Sánchez; Antonio Liras
Journal:  Int J Mol Sci       Date:  2022-07-27       Impact factor: 6.208

4.  Case Report: Novel Mutation of F5 With Maternal Uniparental Disomy Causes Severe Congenital Factor V Deficiency.

Authors:  Lin Cheng; Ying Li; Wenjuan Zhou; Tao Bo
Journal:  Front Pediatr       Date:  2022-06-07       Impact factor: 3.569

5.  Screening platelet function in blood donors.

Authors:  Pascal Pedini; Jean-Baptiste Baudey; Katia Pouymayou; Celine Falaise; Manal Ibrahim-Kosta; Melanie Vélier; Clémence Demerle; Hajer Graiet; Catherine Dragutini; Anne-Marie Dombey; Jacques Chiaroni; Marie Christine Alessi; Christophe Picard
Journal:  Transfusion       Date:  2022-06-24       Impact factor: 3.337

6.  Perioperative management of intrahepatic cholangiocarcinoma patients with hereditary coagulation factor V deficiency: a case report and literature review.

Authors:  Jianlin Lai; Junyi Wu; Yangyang Huang; Hui Cheng; Yannan Bai; Funan Qiu
Journal:  Transl Cancer Res       Date:  2022-09       Impact factor: 0.496

Review 7.  Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease.

Authors:  Prajeeda M Nair; Matthew J Rendo; Kristin M Reddoch-Cardenas; Jason K Burris; Michael A Meledeo; Andrew P Cap
Journal:  Semin Hematol       Date:  2020-07-27       Impact factor: 3.851

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.